-

MedX Health to Present at the Planet MicroCap Virtual Event on April 22, 2021

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, will present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22nd at 12:00 PM EDT.

Mike Druhan, President of Dermatology Services, will present at the event, outlining MedX’s vision for scaling access to its unique dermatological image capture technology and its fully integrated telemedicine platform, DermSecure®. Unlike other teledermatology screening tools available, MedX’s DermSecure® Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.

To access the live presentation, please use the following details:

Planet MicroCap Showcase: VIRTUAL 2021
Date: Thursday, April 22, 2021
Time: 12:00 PM Eastern Time
Webcast: https://www.webcaster4.com/Webcast/Page/2059/40755

To book a one-on-one investor meeting with MedX or to watch the Company’s presentation, please register for the virtual event here: https://planetmicrocapshowcase.com/signup

One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

The Planet MicroCap Showcase: VIRTUAL website is available here: https://planetmicrocapshowcase.com/

For those unable to attend the live presentation, all company presentation webcasts will be available directly on the conference event platform on this link under the tab “Agenda”: https://planetmicrocapshowcase.com/agenda

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain.

www.medx.com

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies you want to know more about; read and watch content from your favorite finance and investing influencers; create your own watchlist and screen for ideas you’re interested in; find out about investor conferences you want to attend - all here on SNN.Network.

Contacts

Bill Mitoulas
Investor Relations
Phone: 416-479-9547
Email: bill@medxhealth.com

MedX Health Corp.

TSX VENTURE:MDX

Release Versions

Contacts

Bill Mitoulas
Investor Relations
Phone: 416-479-9547
Email: bill@medxhealth.com

More News From MedX Health Corp.

MedX Health Corp. Announces 2021 Year End Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2021, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $563,101 for the year ended December 31, 2021, compared with revenue of $530,066 for the year ended December 31, 2020. Revenues from the Company’s SIAscopy®/DermSecure® products decreased by 9.7% from 2020, while revenues from sales of therapeutic laser produc...

MedX Health Corp. and Vitamed Biomedical s.r.l. to Pilot Leading-Edge Teledermatology Screening Platform in Italy

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (MDX - TSXV) and Vitamed Biomedical s.r.l. ("Vitamed") are pleased to announce a Memorandum of Understanding between the companies to pilot MedX’s leading-edge DermSecure® Screening Platform at select pharmacies and general practitioner (GP) clinics in Italy this October. Europe continues to be a strong focus of MedX’s global commercialization strategy, following the ongoing success of its pilot program in the Ne...

MedX Health Corp. Announces Second Quarter 2021 Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V:MDX) announced its results for the three and six-months ended June 30, 2021, which are also available on SEDAR (www.sedar.com). The Company reported revenue of $146,532 for the three-months ended June 30, 2021, compared with revenue of $69,452 for the three-months ended June 30, 2020. Revenues from the Company’s SIAscopy®/DermSecure® products were lower than in 2020, while sales for the therapeutic laser p...
Back to Newsroom